A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01). (6th November 2014) - Clark, Joseph; Flaherty, Lawrence; Ernstoff, Marc; Koon, Henry; Milhem, Mohammed; Militello, Gerald; Agarwala, Sanjiv; Curti, Brendan; Cranmer, Lee; Lao, Christopher D; Logan, Theodore F; Lutzky, Jose; et al.